Compounds > cytarabine

cytarabine and warfarin

cytarabine has been researched along with warfarin in 13 studies

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (15.38)18.2507
2000's6 (46.15)29.6817
2010's4 (30.77)24.3611
2020's1 (7.69)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Aisner, J; Carey, RW; Eaton, WL; Green, MR; Hammond, S; Herndon, JE; Hollis, DR; Maurer, LH; Perry, MC; Skarin, AT; Zacharski, LL1
Fritz, LC; Roth, KA; Sayers, RO; Shindler, KS; Srinivasan, A; Tomaselli, KJ; Wong, AM1
Bruno, AP; d'Orgeix, AT; Laurent, G; Lautier, D; Quillet-Mary, A1
Ardito, R; Cammarota, A; Di Renzo, N; Gallucci, G; Romano, G; Tartarone, A1
Brambilla, G; Castagna, L; Magagnoli, M; Masci, G; Morenghi, E; Pedicini, V; Poretti, D; Santoro, A1
Ariyoshi, N; Kitada, M; Koga, H; Nakamura, H; Nakasa, H; Nakaseko, C; Nishimura, M; Saeki, H; Suzuki, T; Tanaka, H; Yamazaki, S1
Simmons, D; Yu, D; Zhao, Z1

Reviews

1 review(s) available for cytarabine and warfarin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for cytarabine and warfarin

ArticleYear
Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:11

    Topics: Adult; Aged; Amsacrine; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hemorrhage; Humans; Lung Neoplasms; Male; Middle Aged; Recurrence; Survival Analysis; Warfarin

1997

Other Studies

11 other study(ies) available for cytarabine and warfarin

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
In situ immunodetection of activated caspase-3 in apoptotic neurons in the developing nervous system.
    Cell death and differentiation, 1998, Volume: 5, Issue:12

    Topics: Animals; Antibody Specificity; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Brain; Caspase 3; Caspases; Cerebral Cortex; Coumarins; Cross Reactions; Cysteine Proteinase Inhibitors; Cytarabine; Enzyme Precursors; Female; Fluorescent Antibody Technique; Gene Expression; Humans; Jurkat Cells; Male; Mice; Mice, Knockout; Neurons; Oligopeptides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Rabbits

1998
Acute myeloblastic leukemic cells acquire cellular cytotoxicity under genotoxic stress: implication of granzyme B and perforin.
    Blood, 2000, Sep-01, Volume: 96, Issue:5

    Topics: Antigens, CD34; Antineoplastic Agents; Cell Survival; Coumarins; Cytarabine; Cytotoxicity Tests, Immunologic; Daunorubicin; DNA, Antisense; Edetic Acid; Etoposide; Flow Cytometry; Granzymes; HeLa Cells; Humans; Isocoumarins; Jurkat Cells; K562 Cells; Leukemia, Myeloid, Acute; Magnesium Chloride; Membrane Glycoproteins; Perforin; Pore Forming Cytotoxic Proteins; Serine Endopeptidases; Tumor Cells, Cultured; U937 Cells

2000
Venous thromboembolism after high-dose chemotherapy in a patient with Hodgkin's lymphoma receiving the new oral contraceptive ethinylestradiol and drospirenone ("Yasmine").
    Bone marrow transplantation, 2005, Volume: 35, Issue:1

    Topics: Adult; Androstenes; Angiography; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Contraceptives, Oral, Synthetic; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Immunotherapy; International Normalized Ratio; Lynestrenol; Melphalan; Mineralocorticoid Receptor Antagonists; Risk; Risk Factors; Time Factors; Venous Thrombosis; Warfarin

2005
Prophylaxis of central venous catheter-related thrombosis with minidose warfarin in patients treated with high-dose chemotherapy and peripheral-blood stem-cell transplantation: retrospective analysis of 228 cancer patients.
    American journal of hematology, 2006, Volume: 81, Issue:1

    Topics: Administration, Oral; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Catheterization, Central Venous; Cytarabine; Female; Hemorrhage; Humans; Male; Melphalan; Neoplasms; Peripheral Blood Stem Cell Transplantation; Platelet Count; Podophyllotoxin; Retrospective Studies; Risk Factors; Transplantation, Homologous; Venous Thrombosis; Warfarin

2006
Probable interaction between warfarin and antitumor agents used in R-ESHAP chemotherapy.
    Clinical therapeutics, 2008, Volume: 30, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Interactions; Etoposide; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Middle Aged; Pulmonary Embolism; Venous Thrombosis; Warfarin

2008
Cardiovascular risks and bleeding with non-vitamin K antagonist oral anticoagulant versus warfarin in patients with type 2 diabetes: a tapered matching cohort study.
    Cardiovascular diabetology, 2020, 10-10, Volume: 19, Issue:1

    Topics: Aged; Aged, 80 and over; Anticoagulants; Cardiovascular Diseases; Comorbidity; Cytarabine; Diabetes Mellitus, Type 2; England; Female; Hemorrhage; Humans; Incidence; Male; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vitamin K; Warfarin

2020